No Data
Express News | Innovent Receives Second Fast Track Designation From the U.S. FDA for Ibi363 (Pd-1/Il-2Α-Bias Bispecific Antibody Fusion Protein) in Squamous Non-Small Cell Lung Cancer
INNOVENT BIO IBI363 (a PD-1/IL-2α-bias bispecific antibody fusion protein) has again received the USA FDA fast track designation for the treatment of squamous non-small cell lung cancer.
San Francisco and Suzhou, China, February 17, 2025 /PR Newswire/ -- INNOVENT BIO (Hong Kong Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, production, and sales of Innovative Drugs for major diseases such as cancer, autoimmune diseases, metabolism, and ophthalmology, announced that its PD-1/IL-2α-bias bispecific antibody fusion protein IBI363 has received fast track designation from the FDA in the USA, with the intended indication being anti-PD-.
BOCOM INTL: AI-driven new opportunities in the onshore pharmaceutical Sector, giving the Industry a "leading" rating.
With the expectation of continued rollout of favorable policies regarding fiscal and medical insurance/commercial insurance, and the overall Sector valuation still at historical lows, BOCOM INTL believes there is still significant room for recovery in the Sector.
Hong Kong stocks fluctuated | CRO Concept stocks continued to surge in the morning, WUXI BIO (02269) and TIGERMED (03347) both rose over 9%.
In the early session, CRO Concept stocks continued to rise. As of the time of writing, WUXI BIO (02269) is up 9.59%, priced at 22.85 HKD; TIGERMED (03347) is up 9.09%, priced at 31.2 HKD; GENSCRIPT BIO (01548) is up 7.22%, priced at 11.88 HKD.
Hong Kong stocks move | INNOVENT BIO (01801) is currently up nearly 6%. Total product revenue for 2024 has increased by more than 40% year-on-year, and 6 new products are set to be launched in 2025.
INNOVENT BIO (01801) is currently up nearly 6%, as of the time of writing, it has risen by 6.28%, trading at 38.1 Hong Kong dollars, with a transaction value of 0.152 billion Hong Kong dollars.
[Brokerage Focus] BOCOM INTL points to new opportunities in the medical Sector driven by AI technology, focusing on innovation related to AI and opportunities for valuation recovery.
Jingu Finance News | BOCOM INTL stated that multiple pharmaceutical companies have integrated DeepSeek, accelerating the implementation of AI + Medical Services. Many companies in the digital medical field, such as Yidu Technology, announced the integration of DeepSeek-R1 model, and Jiangsu Hengrui Pharmaceuticals and INNOVENT BIO also indicated that they will fully carry out DeepSeek application work. Moreover, the National Healthcare Security Administration has reiterated the reform of payment collection. The administration mentioned the achievements of the settlement reform in Jiangxi Province, where the payment collection cycle for medical supply companies has reduced from half a year to 30 days. The bank pointed out that AI large models empower digital medical services companies, showing significant potential in disease diagnosis/detection. At the same time,
